Oramed Pharmaceuticals Inc. (ORMP) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "ORMP"
      ],
      "issuer_cik": "0001176309",
      "owner_cik": "0001573235",
      "accession_number": "0001213900-26-106530",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "ORAMED PHARMACEUTICALS INC.",
      "issuer_trading_symbol": "ORMP",
      "owner_name": "Hexter Joshua",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "COO & CBO",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 30000,
      "transaction_price_per_share": 4.511,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 1328130,
      "transaction_value": 135330,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."
        },
        {
          "id": "F2",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."
        }
      ]
    },
    {
      "tickers": [
        "ORMP"
      ],
      "issuer_cik": "0001176309",
      "owner_cik": "0001777328",
      "accession_number": "0001213900-26-106531",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "ORAMED PHARMACEUTICALS INC.",
      "issuer_trading_symbol": "ORMP",
      "owner_name": "Gabay Avraham",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 20000,
      "transaction_price_per_share": 4.51,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 861076,
      "transaction_value": 90200,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."
        },
        {
          "id": "F2",
          "description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.